Back to search results

LIGHTSPEED-1: LAT010 for Advanced Solid Tumors

This study, called LIGHTSPEED-1, is testing a new treatment called LAT010 for people with advanced solid tumors. Researchers want to see how safe LAT010 is, how well your body handles it, and if it can shrink tumors. LAT010 is designed to activate certain immune cells (CD8+ T cells and NK cells) that fight cancer, but without the severe side effects often seen with similar treatments. You might receive LAT010 by itself or in combination with another cancer drug called a PD-1 inhibitor. The study is looking for about 150 participants aged 18 or older. The main goals are to track any side effects and see how your body reacts to LAT010.

Study design
This is an open-label, Phase 1/2 study, meaning you and your doctors will know which treatment you are receiving. It will involve about 150 participants and has two parts: a dose-finding phase and a phase to further evaluate safety and effectiveness.
What's involved
You would need to attend study visits, follow treatment plans, and have laboratory tests. In Phase 1, you would receive LAT010 once weekly through an IV for 28 days per cycle.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 18 months, and changes in lab values will be tracked for up to 15 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06277219

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

Recruiting
PHASE1Ages 18+InterventionalTreatment
Latticon Antibody Therapeutics, Inc
~150 participants
Updated 2025-07-08 on ClinicalTrials.gov
What's tested:LAT010LAT010 + ICI

At a glance

Recruiting sites
2 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1)
Measured over Up to 18 months
+3 more outcomes measured

Conditions

Advanced Solid Tumor

Explore related trials

Solid Neoplasm

NCT06277219

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, Chinano site contact published

    Recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, Chinano site contact published

    Recruiting

  • D&H Cancer Research Center

    Margate, Floridano site contact published

    Completed

  • Huntsman Cancer Institute

    Salt Lake City, Utahno site contact published

    Terminated

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John Li, PhD · STUDY_CHAIR · Latticon Antibody Therapeutics, Inc

Who to contact

Lightspeed Study Contact
[email protected]
202-913-8881
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients have histologically or cytologically documented diagnosis of locally advanced or metastatic solid tumors with evidence of progressive disease according to RECIST 1.1, and
Patients are intolerant to or have progressed on all established standard therapies associated with clinical benefit or patients consent that they may be delaying or forgoing treatments known to confer a clinical benefit for their disease, or
No additional established line of standard therapy is available, or
There is a contraindication for the indicated standard therapies in the opinion of the Investigator.

What this trial measures

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1)Up to 18 months

    TEAEs

  • Incidence of changes in clinical laboratory values (Phase 1)Up to 15 months

    Clinical Lab Values

  • Incidence of dose-limiting toxicities (DLTs) (Phase 1)The first treatment cycle (28 days) from Cycle 1 Day 1

    DLT

  • Objective response rate (ORR) per RECIST 1.1 (Phase 2)Up to 24 months

    ORR